Alx Oncology Holdings Inc (ALXO) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Alx Oncology Holdings Inc  (NASDAQ: ALXO)


Alx Oncology Holdings Inc's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Alx Oncology Holdings Inc's ROA in the second quarter of 2026?
Alx Oncology Holdings Inc recorded a cumulative net loss of $-81 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -67.14%.

However, within the Healthcare sector 652 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4202, from total ROA ranking in the first quarter of 2026 at 5000.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 75.15 % 46.9 % -60.31 % -55.01 % -57.39 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -81 -89 -102 -108 -117
Return On Assets (TTM) -67.14 % -86.09 % -114.27 % -96.93 % -85.08 %
ALXO's Total Ranking # 4202 # 5000 # 4374 # 4374 # 4402
Total Assets (TTM) in million 161 178 59 84 92
Seq. Total Assets Change -9.82 % 202.02 % -29.46 % -8.84 % -24.36 %
Seq. Net Income Change - - - - -

ALXO's 5 Years Annual ROA >> Back to ALXO Management Effectiveness >> Compare ALXO ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 299
Sector # 653
Overall # 4062

Return On Assets Statistics
High Average Low
-2.69 %
-51.73 %
-113.63 %
(Dec 31 2020)   (Dec 31 2025)



  News about Alx Oncology Holdings Inc Return on Assets ROA

ALX Oncologys Evorpacept Shows Promise in HER2-Positive Gastric Cancer An In-Depth Analysis of Clinical Trial Data, Stock Performance, and Market Challenges

In a recent announcement, ALX Oncology Holdings Inc. revealed positive topline data from its ASPEN-06 Phase 2 trial, showcasing the potential of Evorpacept in enhancing tumor response in HER2-positive gastric cancer. This breakthrough in cancer treatment has the potential to revolutionize the field and provide hope for patients with this aggressive form of cancer. In this article, we explore the significance of the Phase 2 data and its potential impact on the future of gastric cancer treatment.Evorpacept s Impressive Results:ALX Oncology Holdings Inc. reported significant findings from the ASPEN-06 Phase 2 trial, which demonstrated that Evorpacept, an experimental drug, effectively enhances tumor response in HER2-positive gastric cancer. Gastric cancer is known for its poor prognosis, and the HER2-positive subtype represents a particularly challenging form of the disease. However, the Phase 2 data suggests that Evorpacept has the potential to improve patient outcomes and transform the standard of care for HER2-positive gastric cancer.



Financial Statements
Alx Oncology Holdings Inc's Assets $ 161 million ALXO's Balance sheet
Alx Oncology Holdings Inc's Income $ -18 million Quarterly ALXO's Income Statement
ALXO's Income by Division See ALXO's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change -57.97 % -38.94 % -21.03 % -18.84 % -12.81 %
Total Assets in million 63 149 244 309 380
Y / Y Net Income Change - - - - -
Net Income in million -102 -135 -161 -123 -83
Annual Return On Assets -162.61 % -90.64 % -66 % -40.02 % -21.95 %

ALXO's 5 Years Annual ROA >> Back to ALXO Management Effectiveness >> Compare ALXO ROA to its Competitors



More Return On Assets Ratios
ALXO's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ALXO's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ALXO's Competitors
Subscribers only: Roa for Alx Oncology Holdings Inc's Suppliers
Subscribers only: Return On Assets for ALXO's Customers

You may also want to know
ALXO's Roi ALXO's Inventory Turnover Ratio ALXO's Growth Rates ALXO's Dividend Comparisons
ALXO's Profitability Ratios ALXO's Asset Turnover Ratio ALXO's Dividend Growth
ALXO's Roe ALXO's Valuation Ratios ALXO's Financial Strength Ratios ALXO's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA

Date modified: 2026-09-26T07:38:36+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.